Full-Text Search:
Home|Journal Papers|About CNKI|User Service|FAQ|Contact Us|中文
《Journal of the Fourth Military Medical University》 2009-11
Add to Favorite Get Latest Update

Toremifene and tamoxifen for patients with advanced breast cancer:A meta-analysis of randomized controlled trials

MA Wen1,2,WANG Xiao-Hu1,YANG Ke-Hu2,TIAN Jin-Hui2,LIU Rui-Feng1,21Department of Radiotherapy,Cancer Hospital of Gansu Province,Lanzhou 730050,China,2Evidence-Based Medicine Center,Lanzhou University,Lanzhou 730000,China  
AIM:To evaluate the clinical effectiveness and safety of toremifene(TOR) versus tamoxifen(TAM) for patients with advanced breast cancer.METHODS:This study retrieved relevant randomized controlled trials in PubMed,EMBASE,Cochrane Library,Chinese Biomedical Literature Database,Chinese Scientific Journal Full-text Database,and Chinese Journal Full-text Database up to June 2008.According to the handbook 4.2.6 of Cochrane collaborate,two reviewers assessed the quality of included trials and extracted data independently.The RevMan 4.2.10 software was used for Meta-analysis,relative risk(RR) was used as statistical index for numeration data and weighted mean difference(WMD) was used for measurement data.RESULTS:Ten studies were included(3680 patients).Meta-analysis showed no statistical difference between the 2 groups in 1 and 3-year overall survival rate,but statistical difference was observed in 5-year overall survival rate.The pooled RR and 95% CI were respectively 1.00(0.97,1.03),1.04(0.98,1.09) and 1.06(1.01,1.12).No statistical difference was found between the 2 groups in 1 and 3-year disease-free survival rate but statistical difference was observed in 5-year disease-free survival rate.The pooled RR and 95% CI were respectively 1.00(0.98,1.02),1.05(1.00,1.10),and 1.08(1.02,1.15).No statistical difference was found between the 2 groups in complete response,partial response and objective response.The pooled RR and 95% CI were respectively 1.41(0.90,2.22),0.91(0.71,1.17) and 0.97(0.82,1.14).Adverse reactions in TOR group were lower than those in TAM group,and the quality of life was similar in the 2 groups.CONCLUSION:The results suggest that TOR has better effectiveness and safety than TAM in improving the long-term survival rate for patients with advanced breast cancer.
【CateGory Index】: R737.9
Download(CAJ format) Download(PDF format)
CAJViewer7.0 supports all the CNKI file formats; AdobeReader only supports the PDF format.
【Citations】
Chinese Journal Full-text Database 5 Hits
1 WANG Hong-xia,ZHANG Feng-chun,HUANG Ming-zhu(Department of Oncology,Renji Hospital,School of Medicine,Shanghai Jiaotong University,Shanghai 200127,China);Mitogen-activated protein kinase pathway in antitumor effect of toremifene[J];Journal of Shanghai Jiaotong University(Medical Science);2008-01
2 SUN Xue-min~1,WANG Pei-jun~2,TONG Xiao-wen~1(1.Dept.of Obs & Gyn,Tongji Hospital,affiliated to Tongji University,Shanghai 200065,China;2.Dept.of Radiology,Tongji Hospital,affiliated to Tongji University,Shanghai 200065,China);Clinical Study on Toremifene in the Treatment of Mammary Gland Hyperplasia[J];Journal of Tongji University(Medical Science);2006-05
3 KANG Zhong-cheng,CHENG Yu-jun(Department of Abdominal Surgery,Hunan Tumor Hospital,Changsha 410013,China);Estimation of the Effects of Toremifene on Breast Hyperplasia Disease[J];Chinese Journal of Modern Applied Pharmacy;2006-S3
4 ZHANG Xing-hua,DONG Hai-feng,ZHAO Hong-li.(The Second Hospital of Daqing in Heilongjiang,Daqing 163461,China);Study of Toremifene about its Effect and Mechanism in Treatment of Lung Cancer[J];Medical Recapitulate;2007-15
5 Gao Wanli~ * , Feng Limin, Zhang Hua, et al. ~ * Department of Obstetrics and Gynecology, Beijing Tiantan Hospital, Capital University of Medical Sciences, Beijing 100050, China.;The effects of tamoxifen on expression of Ki-67 antigen,Fas and Fasl in postmenopausal endometrium[J];Chinese Journal of Practical Gynecology and Obstetrics;2006-12
【Secondary Citations】
Chinese Journal Full-text Database 5 Hits
1 HONG Zhuan, ZHENG Xiuli, SUN Xiaofeng, XU Hongxia, ZHOU Zhaofei, WANG Li, XU Xia, PAN Liangxi, FENG Jifeng, HUANG Fulin. Department of Medical Oncology, Jiangsu Cancer Hospital, Nanjing, Jiangsu 210009, P.R.China;High dose tamoxifen in the reversal treatment of multidrug resistance to EP regimen in patients with non-small cell lung cancer[J];Chinese Journal of Lung Cancer;2002-03
2 XU Xue-song, HUANG Yan-ping, ZOU Shi-lin Department of Breast Surgical,First People’s Hospital of Zhenjiang of Jiangsu University, Zhenjiang 212002, P.R.China;Clinical observation on breast cystic hyperplasia treated with toremifene[J];Journal of Qilu Oncology;2005-04
3 ZHU Xiaoli,ZHANG Zhuyi,ZHU Yi. Department of Respirology,The Affiliated Zhongda Hospital,The Southeast University,Nanjing 210009;A study on the expression of estrogen receptor and the effect of Tamoxifen treatment in lung cancer[J];Jiangsu Medical Journal;2002-09
4 CHEN Jie, QIAN Gui sheng, HUANG Gui jun (Institute of Respiratory Disease, Xinqiao Hospital, Third Military Medical University, Chongqing 400037);Advances in multidrug resistance mechanisms in lung cancer[J];China Oncology;2002-03
5 HAN Ming-qiang,HUANG Tao,TIAN Yuan.Thyroid & Breast Surgery Center,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430022,China;Study of Effects of Different Levels of Estradiol on Inhibitory of Tamoxifen on Human Mammary Cancer Cells(ER+) in Vitro[J];Chinese Journal of Bases and Clinics in General Surgery;2005-06
©2006 Tsinghua Tongfang Knowledge Network Technology Co., Ltd.(Beijing)(TTKN) All rights reserved